
Sorafenib 200mg Tablet
Salt Composition: Sorafenib
Expiry Date: 01/2028
Inclusive of all taxes
30 Tablet in Bottle
About The Product
Kidney Cancer
- Sorafenib 200mg Tablet belongs to a group of medications called tyrosine kinase inhibitors.
- It is an anticancer medicine that is used to treat certain types of cancer, including liver cancer, kidney cancer, and thyroid cancer.
- Sorafina is a kinase inhibitor that helps to stop the growth of cancerous cells by blocking the action of an abnormal protein.
Side Effects
Like any other anticancer medicine, Sorafenib 200mg Tablet also shows some side effects, which vary from one person to another according to various health factors. Most of them are mild, and some are serious enough to need immediate medical attention.
Some common side effects include:
- Indigestion
- Hair loss
- Numbness
- Weight loss
- Dizziness
- Diarrhea
- Abdominal pain
- Fatigue
- Anemia
- Fainting
- Lightheadedness
- Muscle cramps
- Anxiety
- Itching
- Vomiting
- Seek medical attention in case of any unusual or severe side effects immediately.
How To Use
- Take Sorafenib 200mg tablet as prescribed by your healthcare provider, depending on your health condition.
- Swallow it as a whole with water and don't chew or crush it.
- This tablet should be taken with food at the same time every day to get effective results.
Safety Advice
Missed Doses
- t is advised not to miss a dose.
- If you skip a scheduled dose of Sorafina tablet, make sure to contact your healthcare provider immediately.
FAQs
Sorafenib 200mg Tablet is used to treat a certain type of cancer, such as liver cancer, kidney cancer, and thyroid cancer, by stopping the growth of cancerous cells.
Reference
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021923s020lbl.pdf
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=93f9c3b2-d4c5-80d3-5421-8b4c29fbf8a6
- Keating, G. M., & Santoro, A. (2009). Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs, 69(2), 223-240.
- Kane, R. C., Farrell, A. T., Saber, H., Tang, S., Williams, G., Jee, J. M., ... & Pazdur, R. (2006). Sorafenib for the treatment of advanced renal cell carcinoma. Clinical cancer research, 12(24), 7271-7278 - https://pubmed.ncbi.nlm.nih.gov/17189398/
- Lennernäs, H., Brisander, M., Liljebris, C., Jesson, G., & Andersson, P. (2024). Enhanced bioavailability and reduced variability of dasatinib and sorafenib with a novel amorphous solid dispersion technology platform. Clinical Pharmacology in Drug Development, 13(9), 985-999 - https://pubmed.ncbi.nlm.nih.gov/38808617/
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
